Oil prices rise from over 1-mth low with Russia crude buyer sanctions in focus
SALT LAKE CITY—Mirza Mansoor Raza, a director at Sera Prognostics , Inc. (NASDAQ:SERA), recently reported a series of stock transactions, according to an SEC filing. The transactions come as the stock trades near its 52-week low of $1.53, having declined over 80% year-to-date. On June 6, Raza sold 107 shares of Class A Common Stock at a price of $1.58 per share, amounting to a total sale value of $169. This sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units (RSUs), as required by the company’s policy.
In addition to the sale, Raza acquired 15,596 shares of Class A Common Stock on June 5 through restricted stock units, with no cash transaction involved. These RSUs are set to vest over the course of one year. Furthermore, Raza was granted stock options for 25,000 shares, exercisable at $1.60 each, also vesting over a year. These grants were part of Sera Prognostics’ Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. According to InvestingPro analysis, the company maintains a strong balance sheet with more cash than debt, though technical indicators suggest the stock is currently in oversold territory. Subscribers can access 10+ additional ProTips and comprehensive insider trading analysis on the platform.
In other recent news, Sera Prognostics reported its Q1 2025 earnings, revealing a narrower-than-expected loss with an EPS of -$0.20, surpassing the forecast of -$0.27. However, revenue fell short of expectations, coming in at $38,000 against a forecast of $200,000, marking a start from zero revenue in the same quarter last year. Despite the revenue miss, the company is focusing on commercialization and market expansion, particularly targeting Medicaid and specific geographic regions. Additionally, Sera Prognostics held its annual stockholders meeting, where stockholders elected two directors and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025. In another development, Sera Prognostics appointed Lee Anderson as its new Chief Commercial Officer, aiming to drive the commercial expansion of its products. Anderson’s previous roles at Genomic Health and Exact Sciences (NASDAQ:EXAS) are noted for contributing to significant revenue growth and successful product launches. These recent developments highlight Sera Prognostics’ strategic efforts to enhance its market presence and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.